CareLit Fachartikel

Combination of mitoxantrone and etoposide in the Treatment of Advanced MyelodysplasticSyndrome/Secondary Acute Myeloid Leukemia - a Multicenter Phase II Study

C. Baldus, L. Balleisen, W. Hirschmann, C. Rudolph, H. Bartels, N. Grobe, T. Zwingers, E. Thiel, W. U. Knauf · TumorDiagnostik & Therapie · 2002 · Heft 02 · S. 57-61

Dokument
848308
CareLit-ID
Jahr
2002
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
TumorDiagnostik & Therapie
Autor:innen
C. Baldus, L. Balleisen, W. Hirschmann, C. Rudolph, H. Bartels, N. Grobe, T. Zwingers, E. Thiel, W. U. Knauf
Ausgabe
Heft 02 / 2002
Jahrgang 23
Seiten
57-61
Erschienen: 2002-01-01 00:00:00
ISSN
0722-219X
DOI
10.1055/s-2002-26771

Zusammenfassung

Abstract BACKGROUND: The combination of mitoxantrone plus etoposide (NOVE) has been shown to be effective in the treatment of relapsed AML and AML in elderly patients. In order to further evaluate this regimen, we conducted a phase II study on NOVE in previously untreated patients diagnosed with sAML/advanced MDS (RAEBt). PATIENTS: A total of 42 evaluable patients with a median age of 61 years (range 37 - 73) were analyzed. Median LDH was 315 U/l (range 67 - 1480) at time of diagnosis. Treatment was initiated within one month from diagnosis in 57 % of patients. NOVE consisted of mitoxantrone 10 mg/sqm d1 - 5 plu…

Schlagworte

Secondary acute myeloid leukemia Myelodysplastic syndrome Mitoxantrone Etoposide TumorDiagnostik & Therapie